By Topic
Meeka Metals (ASX: MEK) Tests Major Support: Can the Downtrend Stabilise?
Meeka Metals faces selling pressure near key support after a volatile year, amid operational challenges and cautious sentiment. As it transitions to production at Murchison, investors are watching whether support holds or signals further downside despite long-term growth potential.
What is the reason for the plummet in Dimerix (ASX: DXB) share price, and how much lower can it go?
Dimerix shares plunged 35–40% amid heavy selling and uncertainty around clinical updates, worsened by weak biotech sentiment. Further downside depends on results and the funding outlook, though volatility in early-stage biotech stocks suggests a potential for sharp rebounds.
.webp&w=828&q=75)
Lumos Diagnostics (ASX: LDX): Shares Keep Sliding Despite Last Year’s Rally
Lumos Diagnostics shares have dropped sharply after last year’s rally, with weak technical signals and dilution concerns weighing on sentiment. Despite long-term optimism around FebriDx and US commercialisation, investors remain cautious due to slow revenue growth and ongoing funding pressures.
Has Neurizon Therapeutics (ASX: NUZ) Formed a Sustainable Long-Term Floor at Its Multi-Year Support Base?
Neurizon Therapeutics (ASX: NUZ) is a clinical-stage biotech developing NUZ-001 for ALS and other neurodegenerative diseases. Despite promising data and global trials, the stock faces pressure from clinical delays, dilution, rising losses, and ongoing uncertainty typical of pre-revenue biotech companies.
Telix Pharmaceuticals (ASX: TLX) Rebounds From Heavy Sell-Off Reignites Investor Optimism
Telix Pharmaceuticals (ASX: TLX) is recovering after a sharp biotech sell-off driven by regulatory and legal concerns. Renewed investor confidence follows strong revenue growth, progress in Phase 3, and a Regeneron partnership, with FY2026 revenue nearing US$1 billion and pipeline milestones advancing.
EBR Systems (ASX: EBR) Slumps to New Lows as Capital Raise Sparks Investor Exit
EBR Systems has fallen sharply after a major capital raise sparked dilution concerns. Despite the sell-off, the company continues to expand the commercialisation of its FDA-approved WiSE CRT heart-failure technology, supported by growing implant volumes, clinical studies, and international regulatory progress.
...